PCSK9 and metabolic syndrome: The present treatment strategies focused on LDL reduction (e.g., statin therapy) are not fundamentally flawed, but in 2024 we may have reached the limit of maximizing CVD risk reduction in those individuals with T2DM and dyslipidemia even with the addition of the newer proprotein convertase subtilisin/kexin type 9 (PCSK-9) inhibitors.